Inozyme Pharma | ARS: Annual Report to Security Holders
Inozyme Pharma | DEFA14A: Others
Inozyme Pharma | DEF 14A: Definitive information statements
Inozyme Pharma | 8-K: Current report
Inozyme Pharma | 4: Statement of changes in beneficial ownership of securities-Officer Treco Douglas A
Inozyme Pharma | 4: Statement of changes in beneficial ownership of securities-Officer Winton Matthew
Inozyme Pharma | 4: Statement of changes in beneficial ownership of securities-Officer Winton Matthew
Inozyme Pharma | 4: Statement of changes in beneficial ownership of securities-Officer Treco Douglas A
Inozyme Pharma | 4: Statement of changes in beneficial ownership of securities-Officer Subramanian Sanjay
Inozyme Pharma | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Inozyme Pharma | 10-K: Annual report
Inozyme Pharma | 8-K: Current report
Inozyme Pharma | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Sofinnova Venture Partners X, L.P. (“SVP X”)(6.9%),Sofinnova Management X, L.P. (“SM X LP”)(6.9%), etc.
Inozyme Pharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Venrock Healthcare Capital Partners II, L.P.(0.0%),VHCP Co-Investment Holdings II, LLC(0.0%), etc.
Inozyme Pharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)
Inozyme Pharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Baker Bros. Advisors LP(0.0%),Baker Bros. Advisors (GP) LLC(0.0%), etc.
Inozyme Pharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-Samlyn Capital, LLC(5.5%),Samlyn, LP(5.5%), etc.
Inozyme Pharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Rock Springs Capital Management LP(5.96%),Rock Springs Capital LLC(5.96%), etc.
Inozyme Pharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-Eventide Asset Management, LLC(5.15%),Finny Kuruvilla, M.D. Ph. D.(5.15%), etc.
Inozyme Pharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Deep Track Capital, LP(0%),Deep Track Biotechnology Master Fund, Ltd.(0%), etc.
No Data